← Therapy pipeline
Investigational · Obesity development

Trevogrumab ± garetosmab + semaglutide

Regeneron

Myostatin blockade, with or without activin A blockade, alongside semaglutide.

myostatinactivin AGLP-1
Other study areas
Body composition
Selected program areas, not approvals. See the full profile for individual trials.
Obesity stagePhase 2Updated as of November 2026
SponsorRegeneron
Targetsmyostatin + activin A + GLP-1
RouteInjection
DevelopmentObesity-specific
01 / Evidence

Selected study results

COURAGE · lower-dose portionLean-mass change by DXA · primary endpointDXA lean mass decreased 4.2% · 52 weeks · Phase 2
Phase 2 · Injection · Peer-reviewed full trial; displayed absolute means from the earlier sponsor report

Lean-mass change by DXA · primary endpoint · 52 weeks

Study focus: Comparative weight management

Lower-dose 52-week results. Absolute arm means below retain the October 1 sponsor source; the journal comparison and confidence intervals are listed separately.

Trevogrumab 75 mg + semaglutide
4.2%
Placebo + semaglutide
7.3%

Adults aged 18–80 years with BMI ≥30 kg/m²; publication Part B, the 52-week lower-dose portion · Trevogrumab 25 or 75 mg with semaglutide 2.4 mg · Trial N=376 · Published analysis: randomized participants receiving at least one dose, efficacy as assigned. Displayed absolute arm means are from the October 1 sponsor report; the journal reports between-group differences. No formal estimand is named in the abstract.. Results & methods ↗ · Publication ↗

October 1 sponsor report · lower-dose DXA lean-mass changes
Arm, each with semaglutide 2.4 mgWeek 26Week 52 (primary)
Placebo−6.7%−7.3%
Trevogrumab 25 mg−4.7%−5.8%
Trevogrumab 75 mg−3.3%−4.2%
Additional results or analyses from this same study
  • Earlier higher-dose and triplet portionThe earlier 26-week triplet result used trevogrumab 400 mg and garetosmab 10 mg/kg with semaglutide. It is a separate portion of the same protocol and should not be combined with the lower-dose 52-week estimates. Follow-up source ↗
  • November 11 journal · 52-week lower-dose Part BPart B n=376. Semaglutide plus placebo lean-mass change was −7.3% (95% CI −8.8 to −5.8). Estimated treatment differences versus semaglutide plus placebo were +1.5 percentage points (95% CI −0.3 to +3.3) with trevogrumab 25 mg and +3.1 points (95% CI +1.3 to +4.9) with 75 mg. These are between-group differences, not total active-arm changes. Follow-up source ↗
  • November 11 journal · separate higher-dose Part A safetyIn the 26-week semaglutide plus trevogrumab 400 mg plus garetosmab 10 mg/kg group, serious adverse events occurred in 14/149, treatment discontinuations in 48/149 and muscle spasms in 61/149. Two deaths occurred in this group; a causal association with treatment was not identified. These are not the 25/75-mg lower-dose arms. Follow-up source ↗

The journal reports no significant fat-mass or body-weight difference in the lower-dose Part B comparisons. Less DXA lean-mass loss does not establish preserved strength or physical function. The higher-dose triplet has a separate safety assessment. The current registry total is not the size of this published analysis.

Each graphic shows results within one study. Alternate analyses and follow-up from that study are labeled together. Study averages are not individual predictions or cross-trial comparisons.

Tolerability

Safety context

The higher-dose triplet had unfavorable tolerability: 14/149 serious adverse events, 48/149 treatment discontinuations and 61/149 muscle spasms in the published Part A. Two deaths occurred in that group; a causal association with treatment was not identified. The paper describes trevogrumab without garetosmab as having safety similar to semaglutide plus placebo. These findings do not establish a physical-function benefit.

02 / How it works

Mechanism at a glance

GLP-1GLP-1Targeted
GIPGIP—
GCGglucagon—
AMYamylin—
OTHOther targetsTargeted

Body-composition and other targets appear alongside hormone pathways in this overview.

Explore the hormone anatomy ↗
03 / Development

Obesity stage by formulation

Antibodies + semaglutideInjection · Study regimen
Phase 2COURAGE completed; full trial published
Milestone → next

Latest: The Lancet published the full COURAGE trial on November 11, 2026, including the separate 52-week lower-dose portion and 26-week higher-dose safety findings.

Next: Further evaluation is needed to determine whether the body-composition changes improve physical function or long-term health.

04 / Study records

Clinical study records

Obesity and weight-management studies appear first. Related-condition trials follow by phase, with focus labels to show what each study evaluates. Study stage and results reporting are listed separately. Results summarized above are identified as peer-reviewed or sponsor reported. Otherwise, the label states whether results were posted to a registry or reported in the linked source.

Obesity and weight-management studies

Phase 2 studies1 record

Phase 2

COURAGE

Weight management
Study: CompletedResults: Peer-reviewed full COURAGE trial published November 11, 2026; no registry results postedStatus reviewed November 2026

Registry records actual completion on October 21, 2026 (posted November 12). The Lancet report calls the 26-week higher-dose cohort Part A and the 52-week lower-dose cohort Part B; the registry uses different part labels after a healthy-volunteer portion. Current registry enrollment is 1,005 and must not replace the publication-specific populations, including lower-dose Part B n=376. No registry results are posted.